Alnylam Pharmaceuticals price to sales ratio ALNY

Market value divided by revenue over the last twelve months, since 2011.

Today, Oct 23, 2026: 6.2×
10-year median: 30.3×
Against its 10-year history: 1st; percentile: 0 is its lowest day, 100 its highest
10-year range: 5.7× to 187×
Peer median: 7.5×

Alnylam Pharmaceuticals' price to sales ratio is 6.2× as of Oct 23, 2026.

That is below its ten-year median of 30.3×, lower than on 99% of days in the last ten years.

Over that time it ranged from 5.7× in Jul 2026 to 187× in Nov 2017.

The median for 10 biotech stocks of a similar size is 7.5×.

Price to sales ratio over time

median 30.3×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	6.2×	5.7×	16.5×
2025	16.5×	13.5×	25.6×
2024	14.7×	9.3×	17.1×
2023	13.9×	11.8×	30.2×
2022	30.4×	17.4×	31.7×
2021	27.1×	25.5×	49.9×
2020	37.7×	36.1×	82.7×
2019	77.5×	60.0×	133×
2018	77.5×	69.7×	179×
2017	170×	80.8×	187×
2016	86.2×	77.7×	200×
2015	139×	108×	197×
2014	189×	66.9×	200×
2013	92.2×	12.7×	94.0×
2012	11.8×	4.4×	13.2×
2011	4.2×	3.0×	4.5×

Against its peers

Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
ALNYAlnylam Pharmaceuticals	6.2×
UTHRUnited Therapeutics	8.0×
INCYIncyte	4.0×
ONCBeOne Medicines	7.0×
EXELExelixis	6.6×
NBIXNeurocrine Biosciences	4.3×
HALOHalozyme Therapeutics	8.6×
TECHBIO-TECHNE	9.4×
REGNRegeneron Pharmaceuticals	5.3×
RGENRepligen	12.7×
KRYSKrystal Biotech	20.9×
Peer median	7.5×

Where Alnylam Pharmaceuticals ranks

#31of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Alnylam Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.